YU75803A - Nova dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja - Google Patents

Nova dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja

Info

Publication number
YU75803A
YU75803A YU75803A YUP75803A YU75803A YU 75803 A YU75803 A YU 75803A YU 75803 A YU75803 A YU 75803A YU P75803 A YUP75803 A YU P75803A YU 75803 A YU75803 A YU 75803A
Authority
YU
Yugoslavia
Prior art keywords
treat diseases
compounds
dihydropyrimidine compounds
formula
substituted dihydropyrimidine
Prior art date
Application number
YU75803A
Other languages
English (en)
Inventor
Spencer David Kimball
Louis J. Lombardo
David B. Rawlins
Hai-Yun Xiao
Robert Joseph Schmidt
David Kent Williams
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of YU75803A publication Critical patent/YU75803A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

U ovom pronalasku se navode jedinjenja sa formulom I i od njih izvedene farmaceutski prihvatljive soli. Jedinjenja koja imaju formulu I indukuju prekid u mitozi, što ih svrstava u red anti-tumorskih sredstava. Jedinjenja sa formulom I se takodje mogu koristiti i u terapiji drugih oboljenja koja se mogu lečiti indukovanjem prekida u mitozi.[The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof.The formula I compounds induce mitotic arrest thereby making them useful as anti-cancer agents.The formula I compounds are also useful for the treatment of other diseases which can be treated by inducing mitotic arrest.
YU75803A 2001-03-29 2002-03-26 Nova dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja YU75803A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27995601P 2001-03-29 2001-03-29

Publications (1)

Publication Number Publication Date
YU75803A true YU75803A (sh) 2006-05-25

Family

ID=23071059

Family Applications (1)

Application Number Title Priority Date Filing Date
YU75803A YU75803A (sh) 2001-03-29 2002-03-26 Nova dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja

Country Status (26)

Country Link
US (1) US6809102B2 (sh)
EP (1) EP1373221A4 (sh)
JP (1) JP2005504725A (sh)
KR (1) KR20030086327A (sh)
CN (1) CN1507435A (sh)
AR (1) AR034585A1 (sh)
BG (1) BG108180A (sh)
BR (1) BR0208405A (sh)
CA (1) CA2442482A1 (sh)
CZ (1) CZ20032645A3 (sh)
EE (1) EE200300474A (sh)
HR (1) HRP20030875A2 (sh)
HU (1) HUP0400350A3 (sh)
IL (1) IL157441A0 (sh)
IS (1) IS6967A (sh)
MX (1) MXPA03008634A (sh)
NO (1) NO20034300L (sh)
PE (1) PE20021013A1 (sh)
PL (1) PL373759A1 (sh)
RU (1) RU2003130961A (sh)
SK (1) SK11062003A3 (sh)
TW (1) TWI228416B (sh)
UY (1) UY27232A1 (sh)
WO (1) WO2002079149A2 (sh)
YU (1) YU75803A (sh)
ZA (2) ZA200306648B (sh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900214B2 (en) * 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
KR100915287B1 (ko) * 2001-12-11 2009-09-03 교와 핫꼬 기린 가부시키가이샤 티아디아졸린 유도체
WO2006018628A1 (en) * 2003-03-07 2006-02-23 Astrazeneca Ab Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer
WO2004078758A1 (en) * 2003-03-07 2004-09-16 Astrazeneca Ab Novel fused heterocycles and uses thereof
AU2004230799B2 (en) 2003-04-18 2010-03-18 Fujifilm Corporation Mitotic kinesin inhibitor
EP1632484A4 (en) * 2003-06-10 2008-09-03 Kyowa Hakko Kogyo Kk D RIV OF THIADIAZOLINE
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
WO2005007124A2 (en) 2003-07-23 2005-01-27 Bristol-Myers Squibb Company Substituted dihydropyrimidine inhibitors of calcium channel function
WO2005037799A1 (en) * 2003-10-16 2005-04-28 Cytokinetics, Inc. Compounds, compositions, and methods
CA2574204A1 (en) * 2004-07-22 2006-01-26 Astrazeneca Ab Fused pyrimidones useful in the treatment and the prevention of cancer
UY29070A1 (es) * 2004-08-18 2006-03-31 Astrazeneca Ab Enantiómeros de heterocíclicos fusionados y sus usos
US20060041128A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
US20100093767A1 (en) * 2004-12-03 2010-04-15 Takeda San Diego, Inc. Mitotic Kinase Inhibitors
CN101193877A (zh) * 2005-03-22 2008-06-04 协和发酵工业株式会社 造血***肿瘤治疗剂
TW200714593A (en) * 2005-03-22 2007-04-16 Kyowa Hakko Kogyo Kk Agent for treatment of solid tumor
EP1908755A4 (en) * 2005-06-24 2009-06-24 Kyowa Hakko Kirin Co Ltd THERAPEUTIC AGENT AGAINST RESTENOSIS
DE102006002065B4 (de) * 2006-01-16 2007-11-29 Infineon Technologies Austria Ag Kompensationsbauelement mit reduziertem und einstellbarem Einschaltwiderstand
CN110464722B (zh) * 2019-06-06 2023-05-23 暨南大学 一类小分子化合物或其药学上可接受的盐在制备抗肿瘤转移药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6211198B1 (en) 1993-04-05 2001-04-03 Synaptic Pharmaceutical Corporation Dihydropyridines and new uses thereof
CZ151297A3 (cs) 1994-11-16 1998-07-15 Synaptic Pharmaceutical Corporation Dihydropyrimidinové sloučeniny a farmaceutické prostředky na jejich bázi
WO1997017969A1 (en) 1995-11-16 1997-05-22 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6172066B1 (en) 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
EP1021185A4 (en) 1996-05-16 2005-09-07 Synaptic Pharma Corp DIHYDROPYRIMIDINE AND ITS USES.
JP2002504931A (ja) 1997-06-18 2002-02-12 メルク エンド カンパニー インコーポレーテッド α１ａアドレナリン受容体拮抗薬
US6080760A (en) 1997-06-18 2000-06-27 Merck & Co., Inc. Alpha 1A adrenergic receptor antagonists
AU1403099A (en) 1997-11-14 1999-06-07 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
CA2323514A1 (en) 1998-04-01 1999-10-07 Yale University Method for selectively modulating the interactions between survivin and tubulin
US6300084B1 (en) 1998-10-08 2001-10-09 The Regents Of The University Of California Anti-mitotic agent screening process
AUPQ171999A0 (en) 1999-07-20 1999-08-12 University Of Sydney, The Neurotropic virus transport
DE19935303A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
DE60028227T2 (de) 1999-10-27 2007-03-29 Cytokinetics, Inc., South San Francisco Chinazolinone benutzende verfahren und zusammenstellungen
US6617115B1 (en) 1999-10-27 2003-09-09 Cytokinetics, Inc. Methods of screening for modulators of cell proliferation
US6284480B1 (en) 2000-04-03 2001-09-04 Cytokinetics, Inc. Antifungal assay
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases

Also Published As

Publication number Publication date
JP2005504725A (ja) 2005-02-17
WO2002079149A3 (en) 2003-02-27
EE200300474A (et) 2003-12-15
NO20034300D0 (no) 2003-09-26
WO2002079149A2 (en) 2002-10-10
ZA200307320B (en) 2004-12-20
HUP0400350A3 (en) 2005-06-28
TWI228416B (en) 2005-03-01
MXPA03008634A (es) 2003-12-08
SK11062003A3 (sk) 2004-08-03
IL157441A0 (en) 2004-03-28
BR0208405A (pt) 2004-03-30
US6809102B2 (en) 2004-10-26
US20030008888A1 (en) 2003-01-09
HRP20030875A2 (en) 2004-08-31
CN1507435A (zh) 2004-06-23
NO20034300L (no) 2003-11-07
EP1373221A2 (en) 2004-01-02
EP1373221A4 (en) 2004-09-29
HUP0400350A2 (hu) 2005-01-28
AR034585A1 (es) 2004-03-03
PE20021013A1 (es) 2002-11-10
ZA200306648B (en) 2004-11-26
CA2442482A1 (en) 2002-10-10
RU2003130961A (ru) 2005-04-10
KR20030086327A (ko) 2003-11-07
PL373759A1 (en) 2005-09-05
UY27232A1 (es) 2002-11-29
BG108180A (en) 2004-09-30
IS6967A (is) 2003-09-24
CZ20032645A3 (cs) 2004-06-16

Similar Documents

Publication Publication Date Title
MXPA03008635A (es) Compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades.
YU75803A (sh) Nova dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja
WO2004106492A3 (en) Bicyclicpyrimidones and their use to treat diseases
YU84603A (sh) Novi inhibitori tirozin kinaze
TW200531689A (en) Therapeutic agents
TW200635903A (en) Therapeutic agents
TW200504034A (en) Therapeutic agents
TW200633986A (en) Therapeutic agents
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
DE60229530D1 (de) Substituierte piperazine als modulatoren des melanocortinrezeptors
RS60503A (en) Substituted alkylamine derivatives and methods of use
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
ATE453636T1 (de) Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren
JO2355B1 (en) Hereditary calcitonin polypeptide receptor antagonists
TNSN04113A1 (en) 3-â-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
TW200716546A (en) Oxindole compounds and their uses as therapeutic agents
UA92503C2 (ru) Соединения 5-(фенилизоксазолилэтокси)-триазол-3-ил-замещенного пиридина для лечения неврологических, психиатрических или болевых расстройств
AU8490901A (en) Urea compounds and methods of uses
TNSN06403A1 (en) 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
MXPA05008438A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6.
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
TW200509933A (en) Therapeutic agents
MXPA06000701A (es) Compuestos de sulfonildihidrobencimidazolona como ligandos de 5-hidroxitriptamina-6.
TW200734324A (en) Therapeutic agents